The Vanguard Group Discloses New Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a Form 8.3 disclosing its interest in Avadel Pharmaceuticals plc. As of February 2, 2026, Vanguard holds 5,789,806 ordinary shares, representing a 5.94% stake in the company. The disclosure is part of the Irish Takeover Panel regulations under Rule 8.3, which mandates the declaration of positions in relevant securities that represent a 1% or more interest.

Vanguard's report indicates a recent purchase of 1,991 shares at a price of 21.56 USD per unit. However, the filing does not note any engagements in cash-settled or stock-settled derivatives. No indemnity, option arrangements, or agreements related to Avadel's securities were reported either.

No additional agreements or future trading intentions were disclosed, and no Supplemental Form 8 was attached to Vanguard's filing. The details focus strictly on Vanguard's current stake in the pharmaceutical company without revealing strategic intentions.